ESMO 2023丨肺癌和其他胸部恶性肿瘤重磅研究一览

作者:肿瘤瞭望   日期:2023/10/9 11:39:44  浏览量:6510

肿瘤瞭望版权所有,谢绝任何形式转载,侵犯版权者必予法律追究。

欧洲肿瘤内科学会(ESMO)年会是欧洲乃至世界最负盛名和最具影响力的肿瘤学会议之一。ESMO 2023将于当地时间10月20~24日于西班牙马德里召开,就肿瘤内科领域热门话题进行提问和辩论,传播最新前沿数据,为世界各地肿瘤学家及相关人员提供交流机会。ESMO官网已披露摘要标题,《肿瘤瞭望》特别总结肺癌和其他胸部恶性肿瘤领域重磅研究(排名不分先后),以飨读者。

编者按:欧洲肿瘤内科学会(ESMO)年会是欧洲乃至世界最负盛名和最具影响力的肿瘤学会议之一。ESMO 2023将于当地时间10月20~24日于西班牙马德里召开,就肿瘤内科领域热门话题进行提问和辩论,传播最新前沿数据,为世界各地肿瘤学家及相关人员提供交流机会。ESMO官网已披露摘要标题,《肿瘤瞭望》特别总结肺癌和其他胸部恶性肿瘤领域重磅研究(排名不分先后),以飨读者。

01
专场类型:Proffered Paper session - NSCLC, metastatic
时间:2023年10月20日16:00 - 17:30
地点:Barcelona Auditorium - Hall 9
LBA63 - SAPPHIRE: Phase 3 Study of Sitravatinib Plus Nivolumab Versus Docetaxel in Patients With Previously Treated Advanced Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
SAPPHIRE:Sitravatinib联合纳武利尤单抗对比多西他赛治疗经治晚期非鳞状非小细胞肺癌(NSCLC)的3期研究
讲者:Hossein Borghaei(费城, 美国)
时间:16:00 - 16:10
LBA64 - Overall Survival from a Phase II Randomised Double-Blind Trial (PERLA) of Dostarlimab (dostar) + Chemotherapy (CT) vs Pembrolizumab (pembro) + CT in Metastatic Non-Squamous NSCLC
在转移性非鳞状NSCLC中,Dostarlimab (dostar) +化疗(CT) 对比帕博利珠单抗(Pembro) + CT的II期随机双盲试验(PERLA)的总生存率
讲者:Solange Peters(洛桑市, 瑞士)
时间:16:10 - 16:20
LBA65 - KRYSTAL-7: Efficacy and safety of adagrasib with pembrolizumab in patients with treatment-na?ve, advanced non-small cell lung cancer (NSCLC) harboring a KRAS G12C mutation
KRYSTAL-7:adagrasib联合帕博利珠单抗一线治疗KRAS G12C突变的晚期非小细胞肺癌(NSCLC) 患者的疗效和安全性
讲者:Marina C. Garassino(芝加哥, 美国)
时间:16:40 - 16:50
LBA66 - Afatinib versus chemotherapy for treatment-na?ve non-small cell lung cancer with a sensitizing uncommon epidermal growth factor receptor mutation: a phase III study (ACHILLES/TORG1834)
阿法替尼对比化疗一线治疗非小细胞肺癌伴致敏性罕见表皮生长因子受体突变:一项III期研究(ACHILLES/TORG1834)
讲者:Satoru Miura(新泻, 日本)
时间:16:50 - 17:00
LBA67 - A Phase 3, Randomized study of atezolizumab plus bevacizumab and chemotherapy in patients with EGFR or ALK mutated in non-small cell lung cancer (ATTLAS, KCSG-LU19-04)
一项3期随机研究(ATTLAS, KCSG-LU19-04):阿替利珠单抗联合贝伐珠单抗和化疗治疗EGFR或ALK突变的非小细胞肺癌患者
讲者:Myung-Ju Ahn(首尔, 韩国)
时间:17:00 - 17:10
02
专场类型:Proffered Paper session - Non-metastatic NSCLC and other thoracic malignancies
时间:2023年10月20日14:00 - 15:45
地点:Sevilla Auditorium - Hall 9
1261O - Neoadjuvant nivolumab (N) + ipilimumab (I) vs chemotherapy (C) in the phase 3 CheckMate 816 trial
在3期CheckMate 816试验中,新辅助纳武利尤单抗(N) + ipilimumab (I)对比化疗
讲者:Mark M. Awad(波士顿,美国)
时间:14:00 - 14:10
LBA56 - Overall survival in the KEYNOTE-671 study of perioperative pembrolizumab for early-stage non-small-cell lung cancer (NSCLC)
在KEYNOTE-671研究中帕博利珠单抗围手术期治疗早期非小细胞肺癌(NSCLC)的总生存率
讲者:Jonathan D. Spicer(蒙特利尔,加拿大)
时间:14:10 - 14:20
LBA60 - Stereotactic body radiation therapy with sequential immunochemotherapy as neoadjuvant therapy in resectable non-small cell lung cancer
LBA60 -立体定向放射治疗序贯免疫化学治疗作为可切除非小细胞肺癌的新辅助治疗
讲者:赵泽锐(中山大学肿瘤防治中心)
时间:14:35 - 14:45
1291O - Radiotherapy boost to 74 Gy based on FDG-PET at 42 Gy of radiochemotherapy (RCT) in patients with inoperable stage III non-small cell lung cancer (RTEP7 – IFCT 1401): a prospective multicentre, open-label, randomised, controlled trial
在不能手术的III期非小细胞肺癌患者中,基于FDG-PET的42 Gy放化疗(RCT)放疗提高至74 Gy:一项前瞻性多中心、开放标签、随机对照试验(RTEP7 – IFCT 1401)
讲者:Gerard Zalcman(巴黎,法国)
时间:14:45 - 14:55
LBA98 - Efficacy and safety of ramucirumab plus carboplatin and paclitaxel in untreated metastatic thymic carcinoma: RELEVENT phase II trial
雷莫西尤单抗联合卡铂和紫杉醇治疗未经治疗的转移性胸腺癌的疗效和安全性:relevance II期试验
讲者:Claudia Proto(米兰,意大利)
时间:15:10 - 15:20
LBA92 - Tarlatamab for patients (pts) with previously treated small cell lung cancer (SCLC): Primary analysis of the phase 2 DeLLphi-301 study
Tarlatamab用于既往治疗过的小细胞肺癌(SCLC)患者:2期delphi -301研究的初步分析
讲者:Luis Paz-Ares(马德里,西班牙)
时间:15:20 - 15:30
03
专场类型:Mini oral session 1 - NSCLC, metastatic
时间:2023年10月21日08:30 - 10:00
地点:Granada Auditorium - Hall 3
LBA68 - FLAURA2: safety and CNS outcomes of first-line (1L) osimertinib (osi) ± chemotherapy (CTx) in EGFRm advanced NSCLC
FLAURA2:一线(1L)奥希替尼(osi)±化疗(CTx)治疗EGFR突变晚期NSCLC的安全性和中枢神经系统结果
讲者:David Planchard(犹太城,法国)
时间:08:30 - 08:35
LBA69 - Aumolertinib plus apatinib versus aumolertinib as first-line treatment in patients with EGFR mutation positive locally advanced or metastatic non-small cell lung cancer (NSCLC): a randomized multicenter study
Aumolertinib 联合阿帕替尼对比Aumolertinib 作为EGFR突变阳性的局部晚期或转移性非小细胞肺癌(NSCLC)患者的一线治疗:一项随机多中心研究
讲者:胡毅(中国人民解放军总医院)
时间:08:35 - 08:40
LBA70 - OSIRAM-1: A multicenter, open label, randomized phase II study of osimertinib plus ramucirumab versus osimertinib alone as initial chemotherapy for EGFR mutation-positive non-squamous non-small cell lung cancer (TORG1833)
OSIRAM-1:一项多中心、开放标签、随机II期研究,将奥希替尼联合雷莫西尤单抗对比奥希替尼作为EGFR突变阳性非鳞状非小细胞肺癌的初始化疗(TORG1833)
讲者:Yoshiro Nakahara(相模原,日本)
时间:08:50 - 08:55
LBA71 - A Multi-Centre Open-Label Randomized Phase II Study of Osimertinib with and without Ramucirumab in TKI-na?ve EGFR-mutant Metastatic NSCLC (RAMOSE trial interim analysis)
一项多中心开放标签随机II期研究:奥希替尼联合和不联合雷莫西尤单抗初始治疗EGFR突变的转移性NSCLC (RAMOSE试验中期分析)
讲者:Xiuning Le(休斯敦,美国)
时间:08:55 - 09:00
1312MO - Combining the antigen-presenting cell activator eftilagimod alpha (soluble LAG-3) and pembrolizumab: overall survival data from the 1st line non-small cell lung carcinoma (NSCLC) cohort of TACTI-002 (Phase II)
结合抗原呈递细胞激活剂eftilagimod α(可溶性LAG-3)和帕博利珠单抗:来自一线非小细胞肺癌(NSCLC)队列的总生存数据(II期)
讲者:Enric Carcereny(巴达洛纳,西班牙)
时间:09:10 - 09:15
1313MO - Safety and preliminary efficacy of AZD7789, a bispecific antibody targeting PD-1 and TIM-3, in patients (pts) with stage IIIB–IV non-small-cell lung cancer (NSCLC) with previous anti-PD-(L)1 therapy
AZD7789是一种靶向PD-1和TIM-3的双特异性抗体,用于先前接受过抗PD-(L)1治疗的IIIB-IV期非小细胞肺癌(NSCLC)患者的安全性和初步疗效
讲者:Benjamin Besse(犹太城,法国)
时间:09:15 - 09:20
1314MO - TROPION-Lung05: Datopotamab deruxtecan (Dato-DXd) in previously treated non-small cell lung cancer (NSCLC) with actionable genomic alterations (AGAs)
TROPION-Lung05: Datopotamab deruxtecan (Dato-DXd)治疗具有可成药基因组改变(AGAs)的非小细胞肺癌(NSCLC)
讲者:Luis Paz-Ares(马德里,西班牙)
时间:09:30 - 09:35
1315MO - Durable efficacy of zenocutuzumab, a HER2 x HER3 bispecific antibody, in advanced NRG1 fusion-positive (NRG1+) non-small cell lung cancer (NSCLC)
Zenocutuzumab,一种HER2 x HER3双特异性抗体,用于晚期NRG1融合阳性(NRG1+)非小细胞肺癌(NSCLC)的持久疗效
讲者:Alison Schram(纽约,美国)
时间:09:35 - 09:40
1316MO - BL-B01D1, a first-in-class EGFRxHER3 bispecific antibody-drug conjugate, in patients with Non-Small Cell Lung Cancer: Updated results from first-in-human phase 1 study
BL-B01D1,一类首个EGFRxHER3双特异性抗体药物偶联物,用于非小细胞肺癌患者:来自首次人体1期研究的最新结果
讲者:张力 (中山大学肿瘤防治中心)
时间:09:40 - 09:45
04
专场类型:Mini oral session 1 - Non-metastatic NSCLC and other thoracic malignancies
时间:2023年10月21日14:45 - 16:15
地点:Salamanca Auditorium - Hall 3
1988MO - Recruitment discontinuation in TREASURE trial (Thoracic RadiothErapy with Atezolizumab in Small cell lUng canceR Extensive disease) due to unexpected safety data
由于意外的安全性数据,TREASURE试验(胸部放疗联合阿替利珠单抗治疗广泛期小细胞肺癌)终止招募
讲者:Farastuk Bozorgmehr(海德堡,德国)
时间:14:45 - 14:50
1989MO - Lurbinectedin (LUR) in combination with pembrolizumab (PBL) in relapsed small cell lung cancer (SCLC): the Phase 1/2 LUPER study
Lurbinectedin (LUR)联合pembrolizumab (PBL)治疗复发性小细胞肺癌(SCLC):1/2期LUPER研究
讲者:Antonio Calles Blanco(马德里,西班牙)
时间:14:50 - 14:55
1990MO - Sacituzumab govitecan (SG) as second-line (2L) treatment for extensive stage small cell lung cancer (ES-SCLC): Preliminary results from the phase 2 TROPiCS-03 basket trial
Sacituzumab govitecan (SG)二线(2L)治疗广泛期小细胞肺癌(ES-SCLC):2期TROPiCS-03篮子试验初步结果
讲者:Afshin Dowlati(克利夫兰,美国)
时间:14:55 - 15:00
LBA99 - First survival data from the NIPU trial; A randomised, open-label, phase II study evaluating nivolumab and ipilimumab combined with UV1 vaccination as second line treatment in patients with malignant mesothelioma
NIPU试验的首个生存数据;一项随机、开放标签、II期研究评估了nivolumab和ipilimumab联合UV1疫苗作为恶性间皮瘤患者的二线治疗
讲者:Aaslaug Helland(奥斯陆,挪威)
时间:15:15 - 15:20
LBA93 - EXTENTORCH: a randomized, phase III trial of toripalimab versus placebo, in combination with chemotherapy as a first-line therapy for patients with extensive stage small cell lung cancer (ES-SCLC)
EXTENTORCH:一项随机III期试验,toripalimab 对比安慰剂,联合化疗作为广泛期小细胞肺癌(ES-SCLC)患者的一线治疗
讲者:柳影(吉林省肿瘤医院)
时间:15:20 - 15:25
1262MO - Impact of a minimal versus CT-scan-based follow-up on patient-reported outcomes for completely resected non-small cell lung cancer (NSCLC) in phase III IFCT-0302 trial
在III期IFCT-0302试验中,基于CT扫描的随访对完全切除非小细胞肺癌(NSCLC)患者报告结果的影响
讲者:Guillaume Eberst(贝桑松市, 法国)
时间:15:35 - 15:40
1263MO - The Impact of PET-CT and Brain MRI for Metastasis Detection among Patients with T1-Stage Lung Cancer: Findings from a Large Cohort Study
PET-CT和脑MRI对T1期肺癌患者转移灶检测的影响:一项大型队列研究的结果
讲者:梁文华(广州医科大学附属第一医院)
时间:15:40 - 15:45
05
专场类型:Mini oral session 2 - NSCLC, metastatic
时间:2023年10月22日08:30 - 10:00
地点:Sevilla Auditorium - Hall 9
1317MO - Updated study results of pelcitoclax (APG-1252) combined with osimertinib in patients (pts) with EGFR-mutant non-small cell lung cancer (NSCLC)
pelcitoclax (APG-1252)联合奥希替尼治疗EGFR突变型非小细胞肺癌(NSCLC)的最新研究结果
讲者:张力 (中山大学肿瘤防治中心)
时间:08:30 - 08:35
1318MO - First-in-Human Study of ABBV-637, an EGFR-targeting BCL-XL–Inhibiting Antibody-Drug Conjugate Combined With Osimertinib (OSI) in Relapsed/Refractory, EGFR-Mutated Non-Small Cell Lung Cancer (NSCLC)
靶向EGFR的BCL-XL抑制抗体药物偶联物ABBV-637联合奥希替尼(OSI)治疗复发/难治性EGFR突变的非小细胞肺癌(NSCLC)的首次人体研究
讲者:Julia K. Rotow(波士顿,美国)
时间:08:35 - 08:40
1320MO - Early evidence of efficacy in patients (pts) with non-small cell lung cancer (NSCLC) with HER2 exon20 insertion (ex20ins) mutations treated in a Phase I study with BAY 2927088
在一项I期研究中,BAY 2927088治疗HER2外显子20插入(ex20ins)突变的非小细胞肺癌(NSCLC)患者的早期疗效证据
讲者:Herbert Ho Fung Loong(中国香港中文大学)
时间:08:40 - 08:45
1319MO - Intracranial efficacy of HER3-DXd in patients with previously treated advanced EGFR-mutated NSCLC: results from HERTHENA-Lung01
HERTHENA-Lung01的结果:HER3-DXd在先前治疗过的晚期EGFR突变NSCLC患者的颅内疗效
讲者:Melissa L. Johnson(那什维尔,美国)
时间:09:00 - 09:05
1321MO - Trastuzumab Deruxtecan (T-DXd) in Patients (pts) With HER2 (ERBB2)-Mutant (HER2m) Metastatic Non–Small Cell Lung Cancer (NSCLC) With and Without Brain Metastases (BMs): Pooled Analyses From DESTINY-Lung01 and DESTINY-Lung02
Trastuzumab Deruxtecan (T-DXd)治疗HER2 (ERBB2)-突变体(HER2m)转移性非小细胞肺癌(NSCLC)伴或不伴脑转移(BMs)患者:来自DESTINY-Lung01和DESTINY-Lung02的汇总分析
讲者:David Planchard(犹太城,法国)
时间:09:05 - 09:10
1324MO - CNS Outcomes of Lazertinib vs Gefitinib in EGFR-mutated Advanced NSCLC: A LASER301 Subset Analysis
Lazertinib对比吉非替尼治疗EGFR突变晚期NSCLC的中枢神经系统预后:LASER301亚组分析
讲者:Ross A. Soo(新加坡市,新加坡)
时间:09:10 - 09:15
1322MO - Insights into Tumour Dissemination and Progression using Longitudinal Imaging and ctDNA in the TRACERx Lung Cancer Study
在TRACERx肺癌研究中,纵向成像和ctDNA对肿瘤传播和进展的洞察
讲者:Wing Kin Liu(伦敦,英国)
时间:09:30 - 09:35
LBA72 - DARWIN II: Deciphering Anti-tumour Response and Resistance to immunotherapy With INtratumour Heterogeneity in NSCLC
DARWIN II:解读非小细胞肺癌的抗肿瘤反应和免疫治疗抵抗与肿瘤内异质性
讲者:Crispin Hiley(伦敦,英国)
时间:09:35 - 09:40
1323MO - Immune evasion across space and time in patients with lung cancer enrolled in the PEACE autopsy study
参与PEACE autopsy研究的肺癌患者跨越时空的免疫逃避
讲者:Sonya Hessey(伦敦,英国)
时间:09:40 - 09:45
06
专场类型:Mini oral session 2 - Non-metastatic NSCLC and other thoracic malignancies
时间:2023年10月23日14:45 - 15:55
地点:Sevilla Auditorium - Hall 9
LBA57 - Neoadjuvant nivolumab (N) + chemotherapy (C) in the phase 3 CheckMate 816 study: 3-y results by tumor PD-L1 expression
CheckMate 816 Ⅲ期研究中的新辅助纳武利尤单抗(N) +化疗(C):PD-L1表达肿瘤的3年结果
讲者:Mariano Provencio Pulla(马哈达翁达,西班牙)
时间:14:45 - 14:50
1264MO - IMpower010: exploratory analysis of disease-free survival (DFS) by TGFβ cancer-associated fibroblast (CAF) gene signature expression in patients (pts) with resected NSCLC treated with atezolizumab (atezo) or best supportive care (BSC)
IMpower010: TGFβ癌症相关成纤维细胞(CAF)基因特征表达在接受阿替利珠单抗(atezo)或最佳支持治疗(BSC)治疗的切除术后非小细胞肺癌患者(pts)中的无病生存(DFS)的探索性分析
讲者:Nasser K. Altorki(纽约,美国)
时间:14:50 - 14:55
LBA58 - Pathological Response to Neoadjuvant Tislelizumab (TIS) Plus Platinum-Doublet (PtDb) Chemotherapy (CT) in Resectable Stage II-IIIA NSCLC Patients (pts) in the Phase 3 (Ph3) RATIONALE-315 Trial
在3期(Ph3) RATIONALE-315试验中,可切除的II-IIIA期非小细胞肺癌患者(pts)对新辅助替雷利珠单抗(TIS)加双铂(PtDb)化疗(CT)的病理反应
讲者:岳东升(天津医科大学肿瘤医院)
时间:14:55 - 15:00
LBA59 - Associations of ctDNA clearance and pathological response with neoadjuvant treatment in patients with resectable NSCLC from the phase 3 AEGEAN trial
3期AEGEAN试验中可切除NSCLC患者ctDNA清除和病理反应与新辅助治疗的关系
讲者:Martin Reck(大汉斯多夫,德国)
时间:15:00 - 15:05
LBA61 - Durvalumab (durva) after sequential chemoradiotherapy (CRT) in patients (pts) with unresectable Stage III NSCLC: Final analysis from PACIFIC-6
无法切除的III期NSCLC患者在序贯放化疗(CRT)后使用度伐利尤单抗(durva):来自PACIFIC-6的最终分析
讲者:Marina C. Garassino(芝加哥,美国)
时间:15:20 - 15:25
1292MO - A phase II study of daily carboplatin plus irradiation followed by durvalumab for unresectable III non-small cell lung cancer patients with PS 2 or elderly (≧75 years): NEJ039A
每日卡铂加放疗加度伐利尤单抗治疗不可切除的伴PS 2或老年(≧75岁)III期非小细胞肺癌患者的II期研究:NEJ039A
讲者:Ryo Ko(静冈市,日本)
时间:15:25 - 15:30
LBA62 - Durvalumab after radiotherapy (RT) in patients with unresectable Stage III NSCLC ineligible for chemotherapy (CT): Primary results from the DUART study
度伐利尤单抗放疗(RT)后治疗无法切除的不适合化疗(CT)的III期NSCLC患者:来自DUART研究的初步结果
讲者:Andrea Riccardo R. Filippi(帕维亚,意大利)
时间:15:30 - 15:35
1293MO - Safety and efficacy of hypo- and conventionally fractionated thoracic radiotherapy plus durvalumab in elderly or frail NSCLC stage III patients unfit for chemotherapy – interim results from the TRADE-hypo trial
TRADE-hypo试验的中期结果:在不适合化疗的老年或体弱NSCLC III期患者中,低和常规分割胸部放疗加度伐利尤单抗的安全性和有效性
讲者:Farastuk Bozorgmehr(海德堡,德国)
时间:15:35 - 15:40
如有遗漏或错误,欢迎广大读者朋友提醒及指正。

 

版面编辑:高金转  责任编辑:卢当鹏

本内容仅供医学专业人士参考


ESMO 2023,肺癌,胸部恶性肿瘤

分享到: 更多